Cellectar and Evestia Clinical Partner to Advance Trial of Radiopharmaceutical in Triple-Negative Breast Cancer
Thursday, September 25, 2025
Cellectar Biosciences has entered into a partnership with Evestia Clinical to support a Phase 1b trial of CLR 125 in triple-negative breast cancer (TNBC).
Triple-negative breast cancer accounts for around 12 per cent of breast cancer cases in the United States. It is defined by the absence of oestrogen receptors, progesterone receptors, and HER2 protein, leaving limited treatment options beyond chemotherapy. The disease is known to grow and spread faster than other breast cancers, with higher rates of relapse and poor prognosis. Studies suggest that approximately a quarter of patients experience recurrence after standard treatments.
CLR 125 is an iodine-125 Auger-emitting radiopharmaceutical candidate designed to target solid tumours, including triple-negative breast, lung, and colorectal cancers. The new study will focus on its potential in TNBC, one of the most aggressive forms of breast cancer.
Evestia Clinical will provide full CRO services for the trial, drawing on its expanded global network and oncology expertise following its recent merger with Atlantic Research Group. The CRO has participated in more than 300 oncology studies across solid and blood cancers, working with leading clinical sites such as the Mayo Clinic.
As part of the collaboration, Cellectar has chosen a Mayo Clinic Network site as a treatment centre, with Dr Pooja Advani of Mayo Clinic serving as lead investigator. This ensures that patients enrolled in the trial will be managed by experienced oncologists with strong expertise in the field.
The initiation of this Phase 1b trial marks an important step towards developing new targeted therapies for TNBC, where there remains a significant unmet medical need.
Source: cellectar.com
